Medication-induced hypophosphatemia: A review

QJM: An International Journal of Medicine

Volumn 103, Issue 7, 2010, Pages 449-459

  Liamis, G ^a   Milionis, H J ^a   Elisaf, M ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; ADEFOVIR; ADRENALIN; AMINOGLYCOSIDE; AZACITIDINE; BISPHOSPHONIC ACID DERIVATIVE; CATECHOLAMINE; CIDOFOVIR; DIURETIC AGENT; ESTROGEN; FRUCTOSE; FUMARIC ACID; GLUCOSE; IFOSFAMIDE; IMATINIB; INDAPAMIDE; INSULIN; IRON; LOOP DIURETIC AGENT; MANNITOL; PARACETAMOL; PHOSPHATE; PHOSPHORUS; STREPTOZOCIN; SURAMIN; TENOFOVIR; TETRACYCLINE; THIAZIDE DIURETIC AGENT; VALPROIC ACID; ZOLEDRONIC ACID;

ACUTE DISEASE; ALCOHOL CONSUMPTION; ANAMNESIS; CELL PROLIFERATION; FANCONI RENOTUBULAR SYNDROME; HEMORRHAGIC CYSTITIS; HUMAN; HYPOPHOSPHATEMIA; INSULIN TREATMENT; INTESTINE ABSORPTION; KIDNEY DYSFUNCTION; METABOLIC ACIDOSIS; NEPHROTOXICITY; PARENTERAL NUTRITION; PATHOPHYSIOLOGY; PHOSPHATE BLOOD LEVEL; PHOSPHATE URINE LEVEL; PHOSPHATURIA; PRIORITY JOURNAL; PSEUDOHYPOPHOSPHATEMIA; RESPIRATORY ALKALOSIS; REVIEW; RISK FACTOR; URINARY EXCRETION; VITAMIN D DEFICIENCY;

EID: 77954267949     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcq039     Document Type: Review

References (99)

1. Gaasbeek A, Meinders AE. Hypophosphatemia: an update on its etiology and treatment. Am J Med 2005; 118:1094-101.
2. Knochel JP. The clinical status of hypophosphatemia: an update. N Engl J Med 1985; 313:447-9.
3. Moe SM. Disorders involving calcium, phosphorus, and magnesium. Prim Care 2008; 35:215-37, v-vi.
4. Knochel JP. The pathophysiology and clinical characteristics of severe hypophosphatemia. Arch Intern Med 1977; 137:203-20.
5. Weisinger JR, Bellorin-Font E. Magnesium and phosphorus. Lancet 1998; 352:391-6.
6. Tejeda A, Saffarian N, Uday K, Dave M. Hypophosphatemia in end stage renal disease. Nephron 1996; 73:674-8.
7. Camp MA, Allon M. Severe hypophosphatemia in hospitalized patients. Miner Electrolyte Metab 1990; 16:365-8.
8. Halevy J, Bulvik S. Severe hypophosphatemia in hospitalized patients. Arch Intern Med 1988; 148:153-5.
9. Takeda E, Taketani Y, Sawada N, Sato T, Yamamoto H. The regulation and function of phosphate in the human body. Biofactors 2004; 21:345-55.
10. Murer H, Hernando N, Forster I, Biber J. Proximal tubular phosphate reabsorption: molecular mechanisms. Physiol Rev 2000; 80:1373-409.
11. Tenenhouse HS. Phosphate transport: molecular basis, regulation and pathophysiology. J Steroid Biochem Mol Biol 2007; 103:572-7.
12. Berndt TJ, Schiavi S, Kumar R. "Phosphatonins" and the regulation of phosphorus homeostasis. Am J Physiol Renal Physiol 2005; 289:F1170-82.
13. Yan X, Yokote H, Jing X, Yao L, Sawada T, Zhang Y, et al. Fibroblast growth factor 23 reduces expression of type IIa Na+/Pi co-transporter by signaling through a receptor functionally distinct from the known FGFRs in opossum kidney cells. Genes Cells 2005; 10:489-502.
14. Levi M, Kempson SA, Lotscher M, Biber J, Murer H. Molecular regulation of renal phosphate transport. J Membr Biol 1996; 154:1-9.
15. Segawa H, Kaneko I, Takahashi A, Kuwahata M, Ito M, Ohkido I, et al. Growth-related renal type II Na/Pi cotransporter. J Biol Chem 2002; 277:19665-72.
16. Hilfiker H, Hattenhauer O, Traebert M, Forster I, Murer H, Biber J. Characterization of a murine type II sodium-phosphate cotransporter expressed in mammalian small intestine. Proc Natl Acad Sci USA 1998; 95:14564-9.
17. Polderman KH, Bloemers FW, Peerdeman SM, Girbes AR. Hypomagnesemia and hypophosphatemia at admission in patients with severe head injury. Crit Care Med 2000; 28:2022-5.
18. Donhowe JM, Freier EF, Wong ET, Steffes MW. Factitious hypophosphatemia related to mannitol therapy. Clin Chem 1981; 27:1765-9.
19. Eisenbrey AB, Mathew R, Kiechle FL. Mannitol interference in an automated serum phosphate assay. Clin Chem 1987; 33:2308-9.
20. Brautbar N, Leibovici H, Massry SG. On the mechanism of hypophosphatemia during acute hyperventilation: evidence for increased muscle glycolysis. Miner Electrolyte Metab 1983; 9:45-50.
21. Roos A, Boron WF. Intracellular pH. Physiol Rev 1981; 61:296-434.
22. Laaban JP, Waked M, Laromiguiere M, Vuong TK, Rochemaure J. Hypophosphatemia complicating management of acute severe asthma. Ann Intern Med 1990; 112:68-9.
23. Squara P, Bleichner G, Aubier M, Parent A, Sollet JP, Murciano D. [Hypophosphoremia during mechanical ventilation for chronic obstructive bronchopathies]. Presse Med 1985; 14:1225-8.
24. Betro MG, Pain RW. Hypophosphataemia and hyperphosphataemia in a hospital population. Br Med J 1972; 1:273-6.
25. Paterson CR. Hypophosphataemia: a dangerous disorder. Nutrition 1996; 12:540-1.
26. Marinella MA. Refeeding syndrome and hypophosphatemia. J Intensive Care Med 2005; 20:155-9.
27. Bode JC, Zelder O, Rumpelt HJ, Wittkamp U. Depletion of liver adenosine phosphates and metabolic effects of intravenous infusion of fructose or sorbitol in man and in the rat. Eur J Clin Invest 1973; 3:436-41.
28. Marinella MA. Refeeding syndrome: an important aspect of supportive oncology. J Support Oncol 2009; 7:11-6.
29. Body JJ, Cryer PE, Offord KP, Heath H 3rd. Epinephrine is a hypophosphatemic hormone in man. Physiological effects of circulating epinephrine on plasma calcium, magnesium, phosphorus, parathyroid hormone, and calcitonin. J Clin Invest 1983; 71:572-8.
30. Ljunghall S, Joborn H, Rastad J, Akerstrom G. Plasma potassium and phosphate concentrations-influence by adrenaline infusion, beta-blockade and physical exercise. Acta Med Scand 1987; 221:83-93.
31. Santana e Meneses JF, Leite HP, de Carvalho WB, Lopes E Jr. Hypophosphatemia in critically ill children: prevalence and associated risk factors. Pediatr Crit Care Med 2009; 10:234-8.
32. Brady HR, Ryan F, Cunningham J, Tormey W, Ryan MP, O'Neill S. Hypophosphatemia complicating bronchodilator therapy for acute severe asthma. Arch Intern Med 1989; 149:2367-8.
33. McCleave DJ, Phillips PJ, Vedig AE. Compartmental shift of potassium-a result of sympathomimetic overdose. Aust N Z J Med 1978; 8:180-3.
34. Prince RL, Monk KJ, Kent GN, Dick I, Thompson PJ. Effects of theophylline and salbutamol on phosphate and calcium metabolism in normal subjects. Miner Electrolyte Metab 1988; 14:262-5.
35. Aibiki M, Kawaguchi S, Maekawa N. Reversible hypophosphatemia during moderate hypothermia therapy for braininjured patients. Crit Care Med 2001; 29:1726-30.
36. Arroliga AC, Guntupalli KK, Beaver JS, Langholff W, Marino K, Kelly K. Pharmacokinetics and pharmacodynamics of six epoetin alfa dosing regimens in anemic critically ill patients without acute blood loss. Crit Care Med 2009; 37:1299-307.
37. Tsimberidou AM, O'Brien SM, Cortes JE, Faderl S, Andreeff M, Kantarjian HM, et al. Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders. Leuk Lymphoma 2002; 43:767-72.
38. Lotz M, Zisman E, Bartter FC. Evidence for a phosphorusdepletion syndrome in man. N Engl J Med 1968; 278:409-15.
39. Chines A, Pacifici R. Antacid and sucralfate-induced hypophosphatemic osteomalacia: a case report and review of the literature. Calcif Tissue Int 1990; 47:291-5.
40. Buell JF, Berger AC, Plotkin JS, Kuo PC, Johnson LB. The clinical implications of hypophosphatemia following major hepatic resection or cryosurgery. Arch Surg 1998; 133:757-61.
41. Crook MA. Hypophosphataemia and hypokalaemia in patients with hypomagnesaemia. Br J Biomed Sci 1994; 51:24-7.
42. Lemann J Jr. Pleuss JA, Gray RW, Hoffmann RG. Potassium administration reduces and potassium deprivation increases urinary calcium excretion in healthy adults [corrected]. Kidney Int 1991; 39:973-83.
43. Elisaf M, Merkouropoulos M, Tsianos EV, Siamopoulos KC. Pathogenetic mechanisms of hypomagnesemia in alcoholic patients. J Trace Elem Med Biol 1995; 9:210-4.
44. Solomon R. The relationship between disorders of K+ and Mg+ homeostasis. Semin Nephrol 1987; 7:253-62.
45. Wu X, Ackermann U, Sonnenberg H. Potassium depletion and salt-sensitive hypertension in Dahl rats: effect on calcium, magnesium, and phosphate excretions. Clin Exp Hypertens 1995; 17:989-1008.
46. Itescu S, Haskell LP, Tannenberg AM. Thiazide-induced clinically significant hypophosphatemia. Clin Nephrol 1987; 27:161-2.
47. Plante GE, Lafreniere MC, Tam PT, Sirois P. Effect of indapamide on phosphate metabolism and vascular reactivity. Am J Med 1988; 84:26-30.
48. Liamis G, Mitrogianni Z, Liberopoulos EN, Tsimihodimos V, Elisaf M. Electrolyte disturbances in patients with hyponatremia. Intern Med 2007; 46:685-90.
49. DiMeglio LA, White KE, Econs MJ. Disorders of phosphate metabolism. Endocrinol Metab Clin North Am 2000; 29:591-609.
50. Milionis HJ, Alexandrides GE, Liberopoulos EN, Bairaktari ET, Goudevenos J, Elisaf MS. Hypomagnesemia and concurrent acid-base and electrolyte abnormalities in patients with congestive heart failure. Eur J Heart Fail 2002; 4:167-73.
51. Mechanick JI, Liu K, Nierman DM, Stein A. Effect of a convenient single 90-mg pamidronate dose on biochemical markers of bone metabolism in patients with acute spinal cord injury. J Spinal Cord Med 2006; 29:406-12.
52. Body JJ, Lortholary A, Romieu G, Vigneron AM, Ford J. A dose-finding study of zoledronate in hypercalcemic cancer patients. J Bone Miner Res 1999; 14:1557-61.
53. Quigley R. Proximal renal tubular acidosis. J Nephrol 2006; 19 (Suppl. 9):S41-5.
54. Izzedine H, Launay-Vacher V, Isnard-Bagnis C, Deray G. Drug-induced Fanconi's syndrome. Am J Kidney Dis 2003; 41:292-309.
55. Kintzel PE. Anticancer drug-induced kidney disorders. Drug Saf 2001; 24:19-38.
56. Micetich KC, Futscher B, Koch D, Fisher RI, Erickson LC. Phase I study of streptozocin- and carmustine-sequenced administration in patients with advanced cancer. J Natl Cancer Inst 1992; 84:256-60.
57. Peterson BA, Collins AJ, Vogelzang NJ, Bloomfield CD. 5-Azacytidine and renal tubular dysfunction. Blood 1981; 57:182-5.
58. Rago RP, Miles JM, Sufit RL, Spriggs DR, Wilding G. Suramin-induced weakness from hypophosphatemia and mitochondrial myopathy. Association of suramin with mitochondrial toxicity in humans. Cancer 1994; 73:1954-9.
59. Stohr W, Paulides M, Bielack S, Jurgens H, Treuner J, Rossi R, et al. Ifosfamide-induced nephrotoxicity in 593 sarcoma patients: a report from the Late Effects Surveillance System. Pediatr Blood Cancer 2007; 48:447-52.
60. Rossi R, Pleyer J, Schafers P, Kuhn N, Kleta R, Deufel T, et al. Development of ifosfamide-induced nephrotoxicity: prospective follow-up in 75 patients. Med Pediatr Oncol 1999; 32:177-82.
61. Skinner R, Pearson AD, English MW, Price L, Wyllie RA, Coulthard MG, et al. Risk factors for ifosfamide nephrotoxicity in children. Lancet 1996; 348:578-80.
62. Oberlin O, Fawaz O, Rey A, Niaudet P, Ridola V, Orbach D, et al. Long-term evaluation of ifosfamide-related nephrotoxicity in children. J Clin Oncol 2009; 27:5350-5.
63. Loebstein R, Atanackovic G, Bishai R, Wolpin J, Khattak S, Hashemi G, et al. Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children. J Clin Pharmacol 1999; 39:454-61.
64. Lee BS, Lee JH, Kang HG, Hahn H, Shin HY, Ha IS, et al. Ifosfamide nephrotoxicity in pediatric cancer patients. Pediatr Nephrol 2001; 16:796-9.
65. Kahn J, Lagakos S, Wulfsohn M, Cherng D, Miller M, Cherrington J, et al. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial. JAMA 1999; 282:2305-12.
66. Decaux G. Tetracycline-induced renal hypophosphatemia in a patient with a syndrome of inappropriate secretion of antidiuretic hormone. Nephron 1988; 48:40-2.
67. Alexandridis G, Liberopoulos E, Elisaf M. Aminoglycosideinduced reversible tubular dysfunction. Pharmacology 2003; 67:118-20.
68. Smith GC, Balfe JW, Kooh SW. Anticonvulsants as a cause of Fanconi syndrome. Nephrol Dial Transplant 1995; 10:543-5.
69. Raschka C, Koch HJ. Longterm treatment of psoriasis using fumaric acid preparations can be associated with severe proximal tubular damage. Hum Exp Toxicol 1999; 18:738-9.
70. Aitken JM, Hart DM, Smith DA. The effect of long-term mestranol administration on calcium and phosphorus homeostasis in oophorectomized women. Clin Sci 1971; 41:233-6.
71. Citrin DL, Wallemark CB, Nadler R, Geiger C, Tuttle K, Kaplan EH, et al. Estramustine affects bone mineral metabolism in metastatic prostate cancer. Cancer 1986; 58:2208-13.
72. Citrin DL, Elson P, Kies MS, Lind R. Decreased serum phosphate levels after high-dose estrogens in metastatic prostate cancer. Possible implications. Am J Med 1984; 76:787-93.
73. Faroqui S, Levi M, Soleimani M, Amlal H. Estrogen downregulates the proximal tubule type IIa sodium phosphate cotransporter causing phosphate wasting and hypophosphatemia. Kidney Int 2008; 73:1141-50.
74. Owen S, Hatfield A, Letvak L. Imatinib and altered bone and mineral metabolism. N Engl J Med 2006; 355:627; author reply 8-9.
75. Osorio S, Noblejas AG, Duran A, Steegmann JL. Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukemia in late chronic phase, and this effect is associated with response. Am J Hematol 2007; 82:394-5.
76. Wesson LG. Homeostasis of phosphate revisited. Nephron 1997; 77:249-66.
77. Liamis G, Milionis H, Elisaf M. A review of drug-induced hyponatremia. Am J Kidney Dis 2008; 52:144-53.
78. Andrade L, Reboucas NA, Seguro AC. Down-regulation of Na+ transporters and AQP2 is responsible for acyclovirinduced polyuria and hypophosphatemia. Kidney Int 2004; 65:175-83.
79. Monteiro JL, De Castro I, Seguro AC. Hypophosphatemia induced by acyclovir. Transplantation 1993; 55:680-2. 80.
80. Kempson SA. Effect of metabolic acidosis on renal brushborder membrane adaptation to low phosphorus diet. Kidney Int 1982; 22:225-33.
81. Levine BS, Ho K, Kraut JA, Coburn JW, Kurokawa K. Effect of metabolic acidosis on phosphate transport by the renal brush-border membrane. Biochim Biophys Acta 1983; 727:7-12.
82. Wrenn KD, Slovis CM, Minion GE, Rutkowski R. The syndrome of alcoholic ketoacidosis. Am J Med 1991; 91:119-28.
83. Voigts A, Kaufman CE Jr. Acidosis and other metabolic abnormalities associated with paint sniffing. South Med J 1983; 76:443-7, 52.
84. Liamis G, Milionis HJ, Elisaf M. A review of drug-induced hypocalcemia. J Bone Miner Metab 2009; 27:635-42.
85. Tolman KG, Jubiz W, Sannella JJ, Madsen JA, Belsey RE, Goldsmith RS, et al. Osteomalacia associated with anticonvulsant drug therapy in mentally retarded children. Pediatrics 1975; 56:45-50.
86. Elisaf M, Merkouropoulos M, Tsianos EV, Siamopoulos KC. Acid-base and electrolyte abnormalities in alcoholic patients. Miner Electrolyte Metab 1994; 20:274-81.
87. Dawson DJ, Babbs C, Warnes TW, Neary RH. Hypophosphataemia in acute liver failure. Br Med J (Clin Res Ed) 1987; 295:1312-3.
88. Jones AF, Harvey JM, Vale JA. Hypophosphataemia and phosphaturia in paracetamol poisoning. Lancet 1989; 2:608-9.
89. Florkowski CM, Jones AF, Guy JM, Husband DJ, Stevens J. Retinol binding proteinuria and phosphaturia: markers of paracetamol-induced nephrotoxicity. Ann Clin Biochem 1994; 31 (Pt 4):331-4.
90. Schmidt LE, Dalhoff K. Serum phosphate is an early predictor of outcome in severe acetaminophen-induced hepatotoxicity. Hepatology 2002; 36:659-65.
91. Schouten BJ, Hunt PJ, Livesey JH, Frampton CM, Soule SG. FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study. J Clin Endocrinol Metab 2009; 94:2332-7.
92. Shimizu Y, Tada Y, Yamauchi M, Okamoto T, Suzuki H, Ito N, et al. Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia. Bone 2009; 45:814-6.
93. Sato K, Shiraki M. Saccharated ferric oxide-induced osteomalacia in Japan: iron-induced osteopathy due to nephropathy. Endocr J 1998; 45:431-9.
94. Sato K, Nohtomi K, Demura H, Takeuchi A, Kobayashi T, Kazama J, et al. Saccharated ferric oxide (SFO)-induced osteomalacia: in vitro inhibition by SFO of bone formation and 1,25-dihydroxy-vitamin D production in renal tubules. Bone 1997; 21:57-64.
95. Shackney S, Hasson J. Precipitous fall in serum calcium, hypotension, and acute renal failure after intravenous phosphate therapy for hypercalcemia. Report of two cases. Ann Intern Med 1967; 66:906-16.
96. Winter RJ, Harris CJ, Phillips LS, Green OC. Diabetic ketoacidosis. Induction of hypocalcemia and hypomagnesemia by phosphate therapy. Am J Med 1979; 67:897-900.
97. Chernow B, Rainey TG, Georges LP, O'Brian JT. Iatrogenic hyperphosphatemia: a metabolic consideration in critical care medicine. Crit Care Med 1981; 9:772-4.
98. Lentz RD, Brown DM, Kjellstrand CM. Treatment of severe hypophosphatemia. Ann Intern Med 1978; 89:941-4.
99. Subramanian R, Khardori R. Severe hypophosphatemia. Pathophysiologic implications, clinical presentations, and treatment. Medicine (Baltimore) 2000; 79:1-8.